Cagrilintide/semaglutide
CagriSema
Sources
company_release, as of 2025-12-18Stale
https://www.novonordisk-us.com/media/press-releases/novo-nordisk-cagrisema-fda-nda-submission.html
Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg.
Novo Nordisk U.S. press release dated Dec. 18, 2025
publication, as of 2025-06-22Stale
https://pubmed.ncbi.nlm.nih.gov/40544433/
The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001).
N Engl J Med 2025;393:635-647, PMID 40544433, abstract
registry, as of 2026-09-30Stale
https://clinicaltrials.gov/study/NCT05567796
Protocol section, NCT05567796 REDEFINE 1, last update posted 2026-09-30
registry, as of 2026-09-30Stale
https://clinicaltrials.gov/study/NCT07564414
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 2500. Conditions Obesity; Type 2 Diabetes. This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participan
ClinicalTrials.gov NCT07564414 protocol and results modules
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07919405
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 1408. Conditions Hypertension; Obesity. This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investiga
ClinicalTrials.gov NCT07919405 protocol and results modules
registry, as of 2026-01-28Stale
https://clinicaltrials.gov/study/NCT05394519
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 1200. Conditions Overweight; Obesity; Type 2 Diabetes Mellitus. This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½
ClinicalTrials.gov NCT05394519 protocol and results modules
registry, as of 2026-02-06Stale
https://clinicaltrials.gov/study/NCT06131437
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 809. Conditions Obesity. This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant
ClinicalTrials.gov NCT06131437 protocol and results modules
registry, as of 2026-09-30Stale
https://clinicaltrials.gov/study/NCT07011667
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 609. Conditions Obesity. This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants
ClinicalTrials.gov NCT07011667 protocol and results modules
registry, as of 2026-09-30Stale
https://clinicaltrials.gov/study/NCT07253285
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 460. Conditions Overweight; Obesity. This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study
ClinicalTrials.gov NCT07253285 protocol and results modules
registry, as of 2026-01-20Stale
https://clinicaltrials.gov/study/NCT06780449
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 400. Conditions Obesity. This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and
ClinicalTrials.gov NCT06780449 protocol and results modules
registry, as of 2026-01-22Stale
https://clinicaltrials.gov/study/NCT05813925
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 331. Conditions Obesity or Overweight. This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in th
ClinicalTrials.gov NCT05813925 protocol and results modules
registry, as of 2026-05-05Stale
https://clinicaltrials.gov/study/NCT06388187
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 300. Conditions Obesity. This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get
ClinicalTrials.gov NCT06388187 protocol and results modules
registry, as of 2026-01-09Stale
https://clinicaltrials.gov/study/NCT05996848
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 300. Conditions Obesity or Overweight. This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants g
ClinicalTrials.gov NCT05996848 protocol and results modules
registry, as of 2026-09-04Stale
https://clinicaltrials.gov/study/NCT07745504
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 285. Conditions Overweight; Obesity. The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active m
ClinicalTrials.gov NCT07745504 protocol and results modules
registry, as of 2026-07-09Stale
https://clinicaltrials.gov/study/NCT07357766
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight. Overall status WITHDRAWN. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 0. Conditions Overweight; Obesity. This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of Cagri
ClinicalTrials.gov NCT07357766 protocol and results modules
registry, as of 2026-09-24Stale
https://clinicaltrials.gov/study/NCT06131372
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 626. Conditions Chronic Kidney Disease; Type 2 Diabetes; Obesity. This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to
ClinicalTrials.gov NCT06131372 protocol and results modules
registry, as of 2026-06-26Stale
https://clinicaltrials.gov/study/NCT07597018
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 234. Conditions Obesity; Overweight. This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide version D or cagrilintid
ClinicalTrials.gov NCT07597018 protocol and results modules
registry, as of 2026-01-08Stale
https://clinicaltrials.gov/study/NCT06267092
A Study of How CagriSema Works on Appetite in People With Excess Body Weight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 164. Conditions Overweight; Obesity. Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss m
ClinicalTrials.gov NCT06267092 protocol and results modules
registry, as of 2026-09-10Stale
https://clinicaltrials.gov/study/NCT07010432
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 144. Conditions Obesity. In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagri
ClinicalTrials.gov NCT07010432 protocol and results modules
registry, as of 2026-05-07Stale
https://clinicaltrials.gov/study/NCT07527195
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health). Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 100. Conditions Obesity. The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they lose weight. Participants wil
ClinicalTrials.gov NCT07527195 protocol and results modules
registry, as of 2026-09-10Stale
https://clinicaltrials.gov/study/NCT07184086
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 80. Conditions Obesity. In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been teste
ClinicalTrials.gov NCT07184086 protocol and results modules
registry, as of 2026-01-08Stale
https://clinicaltrials.gov/study/NCT06207877
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 62. Conditions Obesity. This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight. Participant will either get CagriSema (active medicine) or placebo (a dummy medicine), which has no effect on the body. The treatment participant
ClinicalTrials.gov NCT06207877 protocol and results modules
registry, as of 2025-12-12Stale
https://clinicaltrials.gov/study/NCT04940078
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 40. Conditions Obesity & Overweight. This study will compare two different ways of giving cagrilintide and semaglutide for treating overweight and obesity. The medicines will either be given together in 1 injection or as 2 separate injections. The aim of the study is to find out how the different ways of injection
ClinicalTrials.gov NCT04940078 protocol and results modules